Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.69 |
| ▸ | TK1 | P04183 | 2/20 | 0.53 |
| ▸ | TK2 | O00142 | 2/20 | 0.50 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.48 |
| ▸ | CDA | P32320 | 1/20 | 0.43 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.43 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fialuridine SCHEMBL12658448 | 0.94 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL13702050 | 0.94 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL3084382 | 0.94 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL768344 | 0.94 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL9059414 | 0.94 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL24359134 | 0.94 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL30674 | 0.94 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL20769829 | 0.94 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL773510 | 0.94 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL3084377 | 0.94 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983077-A1 | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM | Alnylam Pharmaceuticals, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3790970-A1 | EXTRAHEPATIC DELIVERY | Alnylam Pharmaceuticals Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| WO-2020257194-A1 | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2019217459-A1 | EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-11-14 | — | — | WO | disclosed |